1. Potential Therapeutic Strategies for Targeting Y-Box-Binding Protein 1 in Cancers
   Jia-Wei Yang et al, 2021, Current Cancer Drug Targets CrossRef
2. RNA m5C regulator-mediated modification patterns and the cross-talk between tumor microenvironment infiltration in gastric cancer
   Qiang Zhang et al, 2022, Frontiers in Immunology CrossRef
3. Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma
   Hailong Ruan et al, 2020, Oncogene CrossRef
4. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity
   Zhen Tao et al, 2019, Cancer Immunology Research CrossRef
5. Decreased MYC-associated factor X (MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphoma
   Takahisa Yamashita et al, 2020, Scientific Reports CrossRef
6. The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities
   Paz Nombela et al, 2021, Molecular Cancer CrossRef
7. Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1
   Lijie Zhou et al, 2021, Clinical and Translational Medicine CrossRef
8. Mechanisms of tRNA-derived fragments and tRNA halves in cancer treatment resistance
   Yue Zhang et al, 2020, Biomarker Research CrossRef
9. Pathogenetic Significance of YBX1 Expression in Acute Myeloid Leukemia Relapse
   Mahmoud B.Y. Gouda et al, 2022, Current Research in Translational Medicine CrossRef
10. Role of RNA modifications in cancer
    Isaia Barbieri et al, 2020, Nature Reviews Cancer CrossRef
11. Role of Main RNA Methylation in Hepatocellular Carcinoma: N6-Methyladenosine, 5-Methylcytosine, and N1-Methyladenosine
    Yating Xu et al, 2021, Frontiers in Cell and Developmental Biology CrossRef
12. Holistic anti-tumor resistance mechanism of YBX1 and its potential as a chemoresistance target in pancreatic ductal adenocarcinoma
    Zheng Li et al, 2023, Holistic Integrative Oncology CrossRef
13. The expression level of CSDAP1 in lung cancer and its clinical significance
    Tongbai Xu et al, 2018, Oncology Letters CrossRef
14. Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma
    Thomas G. Johnson et al, 2019, Frontiers in Cell and Developmental Biology CrossRef
15. Targeting the Y-box Binding Protein-1 Axis to Overcome Radiochemotherapy Resistance in Solid Tumors
    Konstanze Lettau et al, 2021, International Journal of Radiation Oncology*Biology*Physics CrossRef
16. Stress-Induced Phosphorylation of Nuclear YB-1 Depends on Nuclear Trafficking of p90 Ribosomal S6 Kinase
    Aadhya Tiwari et al, 2018, International Journal of Molecular Sciences CrossRef
17. The interaction between PDCD4 and YB1 is critical for cervical cancer stemness and cisplatin resistance
    Dan Liu et al, 2021, Molecular Carcinogenesis CrossRef
18. Translational Regulation by eIFs and RNA Modifications in Cancer
    Linzhu Zhang et al, 2022, Genes CrossRef
19. circ_100984‐miR‐432‐3p axis regulated c‐Jun/YBX‐1/β‐catenin feedback loop promotes bladder cancer progression
    Liang Tong et al, 2021, Cancer Science CrossRef
20. Y-Box Binding Protein 1 Regulates Angiogenesis in Bladder Cancer via miR-29b-3p-VEGFA Pathway
    Dongyang Gao et al, 2021, Journal of Oncology CrossRef
21. 5-Methylcytosine RNA Methyltransferases-Related Long Non-coding RNA to Develop and Validate Biochemical Recurrence Signature in Prostate Cancer
    Ke Wang et al, 2021, Frontiers in Molecular Biosciences CrossRef
22. Cancer Antigen 125 Expression Enhances the Gemcitabine/Cisplatin-Resistant Tumor Microenvironment in Bladder Cancer
    Takahisa Yamashita et al, 2023, The American Journal of Pathology CrossRef
23. RNA modification: mechanisms and therapeutic targets
    Lei Qiu et al, 2023, Molecular Biomedicine CrossRef
24. Dual Targeting of Y-Box Binding Protein-1 and Akt Inhibits Proliferation and Enhances the Chemosensitivity of Colorectal Cancer Cells
    null Maier et al, 2019, Cancers CrossRef